XpresSpa Group to Announce First Quarter 2022 Financial Results on May 16
The Company encourages investors and interested parties to listen via webcast as there is a limited capacity to access the conference call by dialing 1-212-231-2930.
The live and later archived webcast can be accessed from the Investor Relations section of the Company’s website at http://xpresspagroup.com. Visitors to the website should select the “Investors” tab and navigate to the “Events” link to access the webcast.
About
- XpresCheck is a leading on-site airport provider of Covid-19 screening and diagnostic testing with 16 locations in 13 domestic airports. XpresCheck is also partnered with the CDC and Concentric by Ginkgo, conducting biosurveillance monitoring at four major domestic airports (
JFK International Airport ,Newark Liberty International Airport ,San Francisco International Airport , andHartsfield-Jackson Atlanta International Airport ) to identify existing and new SARS-CoV-2 variants. XpresSpa is a leading airport retailer of wellness services and related products, with 45 locations in 21 airports globally.- Treat is a travel health and wellness brand that is providing on-demand access to healthcare through technology and personalized services, including 2 domestic airport locations.
- To further build on XpresSpa Group’s expertise in the health and wellness space, the Company acquired HyperPointe in
January 2022 , a leading digital healthcare and data analytics relationship marketing agency serving the global healthcare industry.
To learn more about XpresCheck, visit: www.XpresCheck.com
To learn more about
To learn more about Treat, visit: www.Treat.com
To learn more about HyperPointe, visit: www.Hyperpointe.com
Twitter: @xprescheck and Instagram: @realxprescheck
Twitter: @XpresSpa and Instagram: @XpresSpa
Twitter: @Treat_Care and Instagram: @treat_care
Investor Relations:
ICR
ir@xpresspagroup.com
(203) 682-8253
Media:
julie@jfprmedia.com
(312) 385-0098
Source: XpresSpa Group, Inc.